Cargando…

Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure

AIMS: Chronic heart failure (CHF) remains a major health issue worldwide. In the present study, we aimed to identify novel circulating biomarkers for CHF using serum proteomics technology and to validate the biomarker in three independent cohorts. METHODS AND RESULTS: The isobaric tags for relative...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Ying‐Ying, Wu, Ting‐Ting, Hou, Xian‐Geng, Yang, Hai‐Tao, Yang, Yi, Xiu, Wen‐Juan, Pan, Ying, Ma, Yi‐Tong, Mahemuti, Ailiman, Xie, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567649/
https://www.ncbi.nlm.nih.gov/pubmed/37417425
http://dx.doi.org/10.1002/ehf2.14451
_version_ 1785119175468908544
author Zheng, Ying‐Ying
Wu, Ting‐Ting
Hou, Xian‐Geng
Yang, Hai‐Tao
Yang, Yi
Xiu, Wen‐Juan
Pan, Ying
Ma, Yi‐Tong
Mahemuti, Ailiman
Xie, Xiang
author_facet Zheng, Ying‐Ying
Wu, Ting‐Ting
Hou, Xian‐Geng
Yang, Hai‐Tao
Yang, Yi
Xiu, Wen‐Juan
Pan, Ying
Ma, Yi‐Tong
Mahemuti, Ailiman
Xie, Xiang
author_sort Zheng, Ying‐Ying
collection PubMed
description AIMS: Chronic heart failure (CHF) remains a major health issue worldwide. In the present study, we aimed to identify novel circulating biomarkers for CHF using serum proteomics technology and to validate the biomarker in three independent cohorts. METHODS AND RESULTS: The isobaric tags for relative and absolute quantitation technology was utilized to identify the potential biomarkers of CHF. The validation was conducted in three independent cohort. Cohort A included 223 patients with ischaemic heart disease (IHD) and 321 patients with ischaemic heart failure (IHF) from the CORFCHD‐PCI study. Cohort B recruited 817 patients with IHD and 1139 patients with IHF from the PRACTICE study. Cohort C enrolled 559 non‐ischaemic heart disease patients with CHF (n = 316) or without CHF (n = 243). We found the expression of a‐1 antitrypsin (AAT) was elevated significantly in patients with CHF compared with that in the patients with stable IHD using statistical and bioinformatics analyses. In a validation study, there was a significant difference between patients with stable IHD and patients with IHF in AAT concentration either in cohort A (1.35 ± 0.40 vs. 1.64 ± 0.56, P < 0.001) or in cohort B (1.37 ± 0.42 vs. 1.70 ± 0.48, P < 0.001). The area under the receiver operating characteristic curve was 0.70 [95% confidence interval (CI): 0.66 to 0.74, P < 0.001] in cohort A and 0.74 (95% CI: 0.72 to 0.76, P < 0.001) in cohort B. Furthermore, AAT was negative correlated with left ventricular ejection fraction (r = −0.261, P < 0.001). After adjusting for confounders using a multivariate logistic regression analysis, AAT remained an independent association with CHF in both cohort A (OR = 3.14, 95% CI: 1.667 to 5.90, P < 0.001) and cohort B (OR = 4.10, 95% CI: 2.97 to 5.65, P < 0.001). This association was also validated in cohort C (OR = 1.86, 95% CI: 1.02 to 3.38, P = 0.043). CONCLUSIONS: The present study suggests that serum AAT is a reliable biomarker for CHF in a Chinese population.
format Online
Article
Text
id pubmed-10567649
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105676492023-10-13 Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure Zheng, Ying‐Ying Wu, Ting‐Ting Hou, Xian‐Geng Yang, Hai‐Tao Yang, Yi Xiu, Wen‐Juan Pan, Ying Ma, Yi‐Tong Mahemuti, Ailiman Xie, Xiang ESC Heart Fail Original Articles AIMS: Chronic heart failure (CHF) remains a major health issue worldwide. In the present study, we aimed to identify novel circulating biomarkers for CHF using serum proteomics technology and to validate the biomarker in three independent cohorts. METHODS AND RESULTS: The isobaric tags for relative and absolute quantitation technology was utilized to identify the potential biomarkers of CHF. The validation was conducted in three independent cohort. Cohort A included 223 patients with ischaemic heart disease (IHD) and 321 patients with ischaemic heart failure (IHF) from the CORFCHD‐PCI study. Cohort B recruited 817 patients with IHD and 1139 patients with IHF from the PRACTICE study. Cohort C enrolled 559 non‐ischaemic heart disease patients with CHF (n = 316) or without CHF (n = 243). We found the expression of a‐1 antitrypsin (AAT) was elevated significantly in patients with CHF compared with that in the patients with stable IHD using statistical and bioinformatics analyses. In a validation study, there was a significant difference between patients with stable IHD and patients with IHF in AAT concentration either in cohort A (1.35 ± 0.40 vs. 1.64 ± 0.56, P < 0.001) or in cohort B (1.37 ± 0.42 vs. 1.70 ± 0.48, P < 0.001). The area under the receiver operating characteristic curve was 0.70 [95% confidence interval (CI): 0.66 to 0.74, P < 0.001] in cohort A and 0.74 (95% CI: 0.72 to 0.76, P < 0.001) in cohort B. Furthermore, AAT was negative correlated with left ventricular ejection fraction (r = −0.261, P < 0.001). After adjusting for confounders using a multivariate logistic regression analysis, AAT remained an independent association with CHF in both cohort A (OR = 3.14, 95% CI: 1.667 to 5.90, P < 0.001) and cohort B (OR = 4.10, 95% CI: 2.97 to 5.65, P < 0.001). This association was also validated in cohort C (OR = 1.86, 95% CI: 1.02 to 3.38, P = 0.043). CONCLUSIONS: The present study suggests that serum AAT is a reliable biomarker for CHF in a Chinese population. John Wiley and Sons Inc. 2023-07-07 /pmc/articles/PMC10567649/ /pubmed/37417425 http://dx.doi.org/10.1002/ehf2.14451 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Zheng, Ying‐Ying
Wu, Ting‐Ting
Hou, Xian‐Geng
Yang, Hai‐Tao
Yang, Yi
Xiu, Wen‐Juan
Pan, Ying
Ma, Yi‐Tong
Mahemuti, Ailiman
Xie, Xiang
Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure
title Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure
title_full Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure
title_fullStr Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure
title_full_unstemmed Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure
title_short Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure
title_sort serum a‐1 antitrypsin as a novel biomarker in chronic heart failure
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567649/
https://www.ncbi.nlm.nih.gov/pubmed/37417425
http://dx.doi.org/10.1002/ehf2.14451
work_keys_str_mv AT zhengyingying seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT wutingting seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT houxiangeng seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT yanghaitao seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT yangyi seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT xiuwenjuan seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT panying seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT mayitong seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT mahemutiailiman seruma1antitrypsinasanovelbiomarkerinchronicheartfailure
AT xiexiang seruma1antitrypsinasanovelbiomarkerinchronicheartfailure